Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Operations (Unaudited)

v3.22.1
Condensed Consolidated Interim Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Expenses        
Research and development $ 3,474 $ 3,843 $ 11,169 $ 7,784
General and administrative 1,884 2,762 6,055 7,091
Merger costs       500
In-process research and development       16,094
Operating Expenses (5,358) (6,605) (17,224) (31,469)
Other income (loss)        
Foreign exchange 1 (1) 6 (3)
Amortization of deferred loan costs   (23)   (74)
Interest, net 1 (6) 3 (20)
Other loss (income) 2 (30) 9 (97)
Net loss for the period (5,356) (6,635) (17,215) (31,566)
Computation of basic loss per share        
Net loss for the period (5,356) (6,635) (17,215) (31,566)
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance       (3,181)
Series A Preferred cash dividend (2) (2) (6) (6)
Net loss for the period attributable to common stockholders $ (5,358) $ (6,643) $ (19,683) $ (34,768)
Basic and fully diluted loss per share $ (0.11) $ (0.23) $ (0.45) $ (1.47)
Basic and fully diluted weighted average number of shares 49,128,000 29,273,000 43,942,000 23,701,000
Preferred Stock Series B        
Computation of basic loss per share        
Preferred stock dividend   $ (6)   $ (15)
Preferred Stock Series C        
Computation of basic loss per share        
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance       $ (3,181)
Preferred stock dividend     $ (2,462)